Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Background Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Summary Each year, the American Heart Association (AHA), in conjunction with the National
Institutes of Health and other government agencies, brings together in a single document the …

Background The risk of cardiovascular disease is increased among persons with human
immunodeficiency virus (HIV) infection, so data regarding primary prevention strategies in …

Although there has been substantial improvement in atherosclerotic cardiovascular disease
(ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and …

The recommendations listed in the present guideline are, whenever possible, evidence
based. An initial extensive evidence review, which included literature derived from research …

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

As early as the 1920s, and subsequently in the 1959 Build and Blood Pressure Study (S1. 5-
1) of almost 5 million adults insured between 1934 and 1954, a strong direct relationship …